PRTA - Prothena Corp PLC Stock Price, Fair Value and News

$18.09-0.20 (-1.09%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PRTA Price Action

Last 7 days

10.5%

Last 30 days

-8.8%

Last 90 days

-21.4%

Trailing 12 Months

-48.4%

PRTA RSI Chart

PRTA Valuation

Market Cap

983.6M

Price/Earnings (Trailing)

-19.32

Price/Sales (Trailing)

4.45

EV/EBITDA

-13.92

Price/Free Cashflow

-9.97

PRTA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PRTA Fundamentals

PRTA Revenue

Revenue (TTM)

221.2M

Rev. Growth (Yr)

3.2K%

Rev. Growth (Qtr)

41.7K%

PRTA Earnings

Earnings (TTM)

-50.9M

Earnings Growth (Yr)

222.51%

Earnings Growth (Qtr)

192.59%

PRTA Profitability

EBT Margin

-27.75%

Return on Equity

-8.75%

Return on Assets

-7.89%

Free Cashflow Yield

-10.03%

PRTA Investor Care

Shares Dilution (1Y)

0.46%

Diluted EPS (TTM)

-0.98

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	221.2M	0	0
2023	54.9M	57.6M	141.0M	91.4M
2022	163.9M	127.2M	90.6M	53.9M
2021	50.8M	100.7M	150.6M	200.6M
2020	769.0K	797.0K	749.0K	853.0K
2019	914.0K	802.0K	752.0K	814.0K
2018	20.9M	14.2M	7.6M	955.0K
2017	7.7M	14.3M	20.9M	27.5M
2016	1.3M	1.3M	1.2M	1.1M
2015	38.5M	26.2M	13.9M	1.6M
2014	21.0M	30.9M	40.9M	50.9M
2013	2.4M	1.9M	1.1M	11.0M
2012	1.0M	1.6M	2.1M	2.7M
2011	0	0	0	507.0K
2010	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Prothena Corp PLC

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual AÃƒÆ’Ã…Â¸-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

CEO	Dr. Gene G. Kinney Ph.D.
WEBSITE	prothena.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	127

Prothena Corp PLC Frequently Asked Questions

What is the ticker symbol for Prothena Corp PLC? What does PRTA stand for in stocks?

PRTA is the stock ticker symbol of Prothena Corp PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Prothena Corp PLC (PRTA)?

As of Tue Oct 29 2024, market cap of Prothena Corp PLC is 983.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRTA stock?

You can check PRTA's fair value in chart for subscribers.

Is Prothena Corp PLC a good stock to buy?

The fair value guage provides a quick view whether PRTA is over valued or under valued. Whether Prothena Corp PLC is cheap or expensive depends on the assumptions which impact Prothena Corp PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRTA.

What is Prothena Corp PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 29 2024, PRTA's PE ratio (Price to Earnings) is -19.32 and Price to Sales (PS) ratio is 4.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRTA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Prothena Corp PLC's stock?

In the past 10 years, Prothena Corp PLC has provided -0.018 (multiply by 100 for percentage) rate of return.